NCT01627795

Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment

A Single-center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment - A Phase IIa Study

• Status: Suspended
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 17 (estimated)
• Sponsor: Oshadi Drug Administration · Industry
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

Malignant mesothelioma is a rare neoplasm that arises most commonly from the mesothelial surfaces of the pleural cavity, occasionally from the peritoneal surface, and rarely from the tunica vaginalis or pericardium. It has an extremely poor prognosis with a median survival of 4 to 13 months for untreated patients 1 and 6 to 18 months for treated patients, regardless of the therapeutic approach. The anticancer activity of Oshadi D and Oshadi R treatment was tested in preclinical studies and in phase I clinical study. Four metastatic mesothelioma patients are treated for 5 to 12 months. The Oshadi D and Oshadi R combination treatment was generally well-tolerated with no dose-limiting toxicities observed.

Conditions

• Mesothelioma

Interventions

Type	Name	Description
DRUG	Oshadi D and Oshadi R	anti cancer agents

Timeline

• Start date: 2016-12-01
• Primary completion: 2018-08-01
• Completion: 2018-12-01
• First posted: 2012-06-26
• Last updated: 2018-04-18

Locations

1 site across 1 country: Israel